20170406 Telix Logo.png
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
October 04, 2021 17:34 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
20170406 Telix Logo.png
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
August 17, 2021 21:26 ET | Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study
November 05, 2019 10:00 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in...
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
August 06, 2019 08:30 ET | Zenith Capital Corp.
This press release is not for dissemination in the United States or through US newswire services CALGARY, Alberta, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith”) announced today...
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
June 27, 2019 08:30 ET | Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting
May 16, 2019 10:00 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 16, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary...
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
March 18, 2019 09:00 ET | Zenith Capital Corp.
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE...
ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
January 23, 2019 01:35 ET | ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
Insight Genetics.png
Insight Genetics Launches First-of-its-kind Test for Triple Negative Breast Cancer
December 03, 2018 09:36 ET | Insight Genetics
NASHVILLE, Tenn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Insight Genetics, Inc. today announced the launch of its proprietary Insight TNBCtype™, a new test for categorizing triple negative breast cancer...
ERYTECH partecipa alle prossime conferenze degli investitori
September 13, 2018 17:30 ET | Erytech Pharma S.A.
LIONE, Francia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), una società biofarmaceutica di fase clinica che sviluppa terapie innovative incapsulando...